Journal · Updated 2026-08-11

Virginia Medicaid and GLP-1s in 2026: Covered, Then Tightened — the BMI 40 Standard, the Form That Changed July 1, and the Renewal Math

By the GLP1ProviderFinder Research Desk · Medically reviewed by Dr. A. Goher, MD · Last reviewed 2026-08-11 · How we verify

What the state's own paper establishes

Two layers of primary documentation. The DMAS bulletin — "Upcoming Changes to Service Authorization Criteria for Weight-Loss Drugs," on the state's Medicaid enterprise site — announces the tightened GLP-1 test: BMI of at least forty, or at least thirty-five with two or more chronic conditions, alongside documentation expectations, and grounds the policy in the state's own numbers: obesity affects more than thirty percent of Virginians, many in the most severe class. Industry reporting places the updated authorization form's effective date at July 1, 2026. The service-authorization form itself, published through Virginia's Medicaid pharmacy-services portal, carries the operational criteria: the general anti-obesity class test of BMI twenty-seven or higher with a weight-related comorbidity; a GLP-1-specific threshold that has read BMI above thirty-seven with a named risk factor — dyslipidemia, hypertension, or type 2 diabetes; trial and failure of (or intolerance to) the non-GLP-1 agents first, with managed-care plan forms specifying three-month trials; no concurrent GLP-1s; oral formulations only with a documented medical contraindication to injectables or documented injectable failure; and the renewal rule — five percent weight loss against the last authorization extends approval by six months. Because the bulletin's tightened thresholds and the form's published test differ, the operative question for any individual application is which version of the form your plan is processing this month — ask your prescriber's office to pull the current SA form before submitting, not after a denial.

Ages, drugs, and the managed-care layer

The drug list is the standard covering-state trio, with age minimums that matter for families: Wegovy and Saxenda from age twelve, Zepbound from eighteen. Most Virginia enrollees receive drug benefits through managed-care organizations, whose PA forms restate the state test with plan-level detail — the step-therapy specifics and the needle-phobia documentation standard for oral requests appear on the plan forms — so the plan's current form, not any summary, governs the submission. The prior-authorization guide's documentation checklist maps onto Virginia's requirements almost line for line, and the five-percent renewal rule means the documentation job never fully ends: weigh-ins on the record, on schedule, are what keep an approval alive.

One aggregator conflict, resolved on primary evidence

At least one state-by-state aggregator currently lists Virginia's fee-for-service program as not covering the obesity indication at all. Set against the state's own DMAS bulletin announcing GLP-1 weight-loss criteria, the live service-authorization form carrying those criteria, and both major trackers listing Virginia as covering, the primary evidence decides this one: Virginia covers, strictly. We flag the conflict anyway because it illustrates the method — where primary documents exist, they outrank any tracker, including ours; where they don't, as on our Wisconsin page, we say so instead of guessing. Errors land on the corrections log, dated.

The doors and the floor, Virginia edition

For enrollees the tightened test excludes: the diabetes door (Ozempic, Mounjaro) is federally required everywhere; the non-weight indication doors — cardiovascular risk reduction, obstructive sleep apnea, kidney disease, MASH — generally must be covered with prior authorization under federal rebate-program rules, mapped in the indication-door playbook; the under-21 EPSDT path continues, made more relevant by Virginia's age-twelve minimums; and the cash floor — compounded semaglutide near one hundred dollars a month, tirzepatide under one hundred seventy on current promotional cards — carries the standing verification homework. The national record lives at the Medicaid hub and the 2026 change ledger.

This article is pricing research, not medical advice. Verify figures at the provider's checkout. Nothing here is medical advice.